575 Results (Page 2 of 23)
China Markets Research Reports
China Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market Analysis
This report presents a strategic analysis of the China Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the China Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market, offering unmatched value, accuracy, and expert insights.
China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Analysis
China Duchenne Muscular Dystrophy (DMD) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A genetic condition known as Duchenne muscular dystrophy (DMD) is characterised by advancing muscle weakness and degeneration as a result of changes to a protein called dystrophin, which aids in maintaining healthy muscle cells. The market is expanding as a result of favourable government initiatives that provide appropriate reimbursement policies and promote target-specific treatments. Rapid urbanisation, better medical infrastructure, the emergence of product premiumization, and rising disposable incomes among the general populace are a few other drivers generating profitable growth potential in the industry. Sarepta Therapeutics, PTC Therapeutics, Pfizer, Bristol-Myers Squibb, Italfarmaco, Santhera Pharmaceuticals, and many more are Global companies in the DMD Therapeutics market.
China Cardiac Monitoring Devices Market Analysis
This report presents a strategic analysis of the China Cardiac Monitoring Devices Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the China Cardiac Monitoring Devices Market, offering unmatched value, accuracy and expert insights.
China Over The Counter (OTC) Analgesics Market Analysis
This report presents a strategic analysis of the China Over The Counter (OTC) Analgesics Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the China Over The Counter (OTC) Analgesics Market, offering unmatched value, accuracy and expert insights.
China Conjunctivitis Therapeutics Market Analysis
The China Conjunctivitis Therapeutics Market was valued at $330 Mn in 2022 and is predicted to grow at a CAGR of 6.9% from 2023 to 2030, to $562 Mn by 2030. The key drivers of this industry include the rising burden of conjunctivitis, the evolving treatment landscape in the industry, and supportive government initiatives. The industry is primarily dominated by players such as Allergan, Bausch & Lomb, Alembic, Hao Pharma, Novartis, Santen, and Shanghai Fosun among others.
China Electronic Health Records Market Analysis
China's Electronic Health Records market size was valued at $2.27 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.5% from 2022 to 2030 and will reach $3.49 Bn in 2030. China's EHR market growth can be attributed to the surging need for remote monitoring and chronic disease management. The market is segmented by product type, application type, and end user. The key market players are iSoftStone, Neusoft Medical Systems, Mindray Medical International, GE Healthcare, and others.
China Chronic Pain Therapeutics Market Analysis
The China Chronic Pain Therapeutics Market is anticipated to experience a growth from $5.973 Bn in 2022 to $10.573 Bn by 2030, with a CAGR of 7.4% during the forecast period of 2022-2030. The key drivers of the chronic pain management market in China are the increased prevalence of chronic conditions, the aging population and associated comorbidities, increasing healthcare awareness, and the rising demand for non-opioid pain management alternatives. The China Chronic Pain Therapeutics Market encompasses various players across different segments, including Pfizer, Johnson & Johnson, Merck, Sanofi, AstraZeneca, Innovent Biologics, Shanghai Pharmaceuticals, Henlius Medical, BGI Genomics, Shanghai Fosun Pharma, etc., among various others.
China Electronic Records Management Solutions Market Analysis
China's electronic records management solutions market size was valued at $xx Mn in 2022 and is estimated to expand at a CAGR of xx% from 2022 to 2030 and will reach $xx Mn in 2030. The market is segmented by solution and deployment. The Chinese government has put in place a number of programs to encourage the use of electronic records management tools. The "Digital China" policy, for instance, seeks to digitize all governmental services and encourage the growth of digital infrastructure. The key market players are Wuhan Baocheng Technology, Beijing Wisdom Watch Information Technology, Beijing Sanxia Technology Development, and others.
China Oral Care Market Analysis
China's oral care market was valued at $2.8 Bn in 2022 and is estimated to expand at a CAGR of 7.7% from 2022 to 2030 and will reach $5.1 Bn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Hawley & Hazel, Yunnan Baiyao Group, Shanghai Jahwa United Co, Guangzhou Lion Company, Fujian Sanli Group, Midmark, iByer Dental Group, Bybo Dental Group, ChengDu Huamei Dental Chain Co, Sirona Dental Systems, and Foshan.
China Retail Pharmacy Market Analysis
China's Retail Pharmacy Market is projected to grow from $83.49 Bn in 2022 to $159.17 Bn by 2030, registering a CAGR of 8.4% during the forecast period of 2022–30. Advancements in technology such as electronic prescriptions, telemedicine, online ordering, and home delivery services are driving the market growth. There are some of the major companies operating in the US Retail Pharmacy Market include Sinopharm, Yonghui Superstores, and Wal-Mart.
China Central Nervous System (CNS) Therapeutics Market Analysis
The China Central Nervous System (CNS) Therapeutics Market was valued at US $16.881 Bn in 2022 and is predicted to grow at a CAGR of 7.9% from 2023 to 2030, to US $31.051 Bn by 2030. The key drivers of this industry include the increasing prevalence of CNS disorders, growing consumer demand, and supportive government policies. The industry is primarily dominated by players such as AbbVie, Pfizer, Shanghai Fosun, Green Valley, Lundbeck, and Hualan among others.
China Biosimilars Market Analysis
China's biosimilar market size was valued at $1.54 Bn in 2022 and is estimated to expand at a CAGR of 23.7% from 2022 to 2030 and will reach $8.46 Bn in 2030. The market is segmented by product type and indication type. The China biosimilar market will grow as the Chinese biosimilar market is driven by its cost-effective manufacturing capabilities. The key market players are Bio-Thera Solutions (CHN), Innovent Biologics (CHN), Shanghai Henlius Biotech (CHN), MabSpace Biosciences Co. (CHN), and others.
China Artificial Intelligence (AI) in Healthcare Market Analysis
China's Artificial Intelligence (AI) in the healthcare market is projected to grow from $0.55 Bn in 2022 to $11.91 Bn by 2030, registering a CAGR of 46.72% during the forecast period of 2022-30. The market will be driven by rising demand for healthcare services & a robust startup and innovation ecosystem. The market is segmented by healthcare components & by healthcare applications. Some of the major players include Google Health, Tencent Trusted Doctors & NERVTEX.
China Nutritional Supplements Market Analysis
By 2030, it is anticipated that the China nutrition and supplements market will reach a value of $65.74 Bn from $30.67 Bn in 2022, growing at a CAGR of 10% during 2022-2030. The market is primarily dominated by local players such as Health Food Company, Fancl Corporation, and CSPC Pharmaceutical Group. The market for Nutrition and supplements in China is primarily driven by government regulations, increasing customer awareness, and e-commerce platforms. The China nutrition and supplements market in China is segmented by Type, Product, application, and Distribution Channel.
China In Vitro Fertilisation (IVF) Service Market Analysis
This report presents a strategic analysis of the China In Vitro Fertilization (IVF) Service Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about China's In Vitro Fertilization (IVF) Service Market, offering unmatched value, accuracy, and expert insights.
China Artificial Intelligence (AI) in Medical Imaging Market Analysis
China artificial intelligence (AI) in medical Imaging market size was valued at $121 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 36.9% from 2022 to 2030 and will reach $ 1488. The market is segmented by AI technology, solution, modality, application, and end User. Due to developments in AI and machine learning algorithms that are enabling the creation of more precise and effective medical imaging software, the China Artificial Intelligence (AI) in the Medical Imaging market will expand. Some of the key players in this market are Infervision (CHN), Yitu Healthcare (CHN), 12 Sigma Technologies (CHN), Huiying Medical Technology (CHN), Deepwise (CHN), United Imaging (CHN), Airdoc(CHN), IBM Watson Health (USA), NVIDIA Corporation (USA), and others.
China Alzheimer’s Therapeutics Market Analysis
China alzheimer’s therapeutics market valued at $386 Mn in 2022, projected to reach $864 Mn by 2030 with a 10.6% CAGR. One key factor propelling the market for Alzheimer's treatment medications is the rising incidence of Alzheimer's disease which is driven by an aging population. The leading pharmaceutical companies currently operating in the market are Shanghai Green Valley Pharmaceutica, Eisai Co., Eli Lilly, Lundbeck, Johnson and Johnson, Novartis, Pfizer, Chongqing Zhifei Biological Products, Hengrui Medicine Co. and Jiangsu Hengrui Medicine.
China Atopic Dermatitis Therapeutics Market Analysis
The China Atopic Dermatitis Therapeutics Market was valued at US $0.99 Bn in 2022, and is predicted to grow at (CAGR) of 10.3% from 2023 to 2030, to US $2.16 Bn by 2030. The key drivers of this industry include a surge in the prevalence of Atopic Dermatitis (AD), emerging innovative therapeutics and increased awareness. The industry is primarily dominated by players such as Pfizer, Sanofi, Novartis, Galderma, AbbVie, Viatris, Bayer, and AstraZeneca, among others.
China Atherosclerosis Therapeutics Market Analysis
China Atherosclerosis Therapeutics Market was valued at $225 Mn in 2022 and is estimated to reach $393 Mn in 2030, exhibiting a CAGR of 7.2% during the forecast period. The market for atherosclerosis therapeutics is expected to rise as a result of the increasing prevalence of cardiovascular illnesses that have been exacerbated by unhealthy eating habits, sedentary lifestyles, and an aging population worldwide. The top leading pharmaceutical companies presently operating in the industry are Pfizer, Novartis, AstraZeneca, Sanofi, Merck & Co., China Resources Pharmaceutical Group, Huahai Pharmaceutical Group, Jiangsu Hengrui Medicine Co., Qilu Pharmaceutical Co. and Yisheng Pharmaceutical Co.
China HIV Drugs Market Analysis
China HIV Drugs Market is at around $2.55 Bn in 2023 and is projected to reach $3.61 Bn in 2030, exhibiting a CAGR of 5.1% during the forecast period. Increasing HIV/ AIDS prevalence, healthcare infrastructure improvement and new drug approvals and developments are all driving market expansion. The market is dominated by key players like Sinopharm, Jiangsu Hengrui Medicine, Shanghai Fosun Pharmaceuticals, ViiV Healthcare, Gilead Sciences, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, and AbbVie Inc.
China Antifungal Drugs Market Analysis
China Antifungal Drugs Market is at around $1.3 Bn in 2023 and is projected to reach $1.8 Bn in 2030, exhibiting a CAGR of 5.3% during the forecast period. The factors propelling the market's expansion include government initiatives and healthcare policies, enhanced diagnosis and awareness, epidemiological shifts, and antifungal resistance. The market is dominated by key players like Novartis AG, Merck & Co., Inc., Pfizer Inc., Abbott Laboratories, Astellas Pharma Inc., GlaxoSmithKline plc, Bayer AG, Glenmark Pharmaceuticals Limited, Sanofi S.A., and Gilead Sciences Inc.
China Glucaric Acid Market Analysis
China Glucaric Acid Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Key drivers of the glucaric acid market include the growing demand in various industries, driven by its applications and eco-friendly properties, increased consumer awareness of sustainability, and ongoing research and development efforts to explore new applications and production methods for glucaric acid. Global Players in Glucaric Acid Market are Rennovia Inc., Rivertop Renewables, Haihang Industry Co., Hebei Long Hai Import and Export Trade Co., Haihang Industry (Jinan) Co., Alfa Chemistry, Tokyo Chemical Industry Co., AK Scientific and Biosynth Carbosynth.
China Glutathione Market Analysis
China Glutathione Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The increased prevalence of chronic diseases, demand in the cosmetics and beauty industry, and sports nutrition and performance enhancement are key drivers of the glutathione market. Kyowa Hakko Bio Co., Shandong Jincheng Biological Pharmaceutical Co., Kohjin Life Sciences, NOW Health Group, Merck KGaA, Kaiping Genuine Biochemical Pharmaceutical Co., Mitsubishi Tanabe Pharma Corporation, Shenzhen GSH Bio-Technology Co., Energetic Nutrition, and TCI Chemicals are the global players in the glutathione market.
China Gram Positive Bacterial Infections Market Analysis
China Gram Positive Bacterial Infections Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Key drivers of the gram-positive bacterial infections market include the increasing prevalence of these infections, the emergence of antibiotic resistance, technological advancements in diagnostics and treatments, and the growing healthcare infrastructure, leading to higher demand for effective treatments and the need for innovative solutions to combat these infections. Global Players in Gram positive Bacterial Infections market are Pfizer Inc., Merck & Co., GlaxoSmithKline, Novartis AG, Sanofi S.A., Johnson & Johnson Services, AbbVie Inc., Bayer AG, AstraZeneca plc and Eli Lilly and Company.
China Gynecology Drugs Market Analysis
China Gynecology Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Key drivers of the gynecology drugs market include the increasing prevalence of gynecological disorders, growing awareness and focus on women's health, technological advancements, and supportive government initiatives promoting women's healthcare. Key Global Players in Gynecology Drugs Market are Bayer AG, Pfizer Inc., Merck & Co., Novartis AG, Johnson & Johnson, AbbVie Inc., Allergan plc, Eli Lilly and Company, AstraZeneca plc and GlaxoSmithKline plc.
